BAXTER INTERNATIONAL INC SEC 10-K Report

robot
Abstract generation in progress

Baxter International Inc. released its 2025 10-K report, detailing a 6% increase in total net sales to $11,244 million but also reporting a net loss of $(957) million attributable to stockholders due to significant special items and impairments. The company is actively streamlining operations through divestitures like its Kidney Care and BioPharma Solutions businesses to focus on core segments and reduce debt, while facing challenges from heavy indebtedness, market competition, supply chain disruptions, and management transitions. Baxter plans to continue optimizing its portfolio, pursue cost savings, and manage its financial position to improve future growth and profitability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)